Poulou AC, Goumas KE, Dandakis DC, Tyrmpas I, Panagiotaki M, Georgouli A, Soutos DC, Archimandritis A. Microproteinuria in patients with inflammatory bowel disease: Is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J Gastroenterol 2006; 12(5): 739-746 [PMID: 16521187 DOI: 10.3748/wjg.v12.i5.739]
Corresponding Author of This Article
Dr Androniki Poulou, Red Cross Hospital of Athens, Spetson 25, Voula, 16673 Athens, Greece. ddandakis@yahoo.com
Article-Type of This Article
Clinical Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 7, 2006; 12(5): 739-746 Published online Feb 7, 2006. doi: 10.3748/wjg.v12.i5.739
Table 1 Incidence of abnormal microproteinuria in patients with active and inactive IBD (%)
Ulcerative colitis (n = 194)
Crohn's disease (n = 83)
Active (n = 49)UCAI ≥ 6
Inactive (n = 145)UCAI < 6
P
Active (n = 15)CDAI ≥ 150
Inactive (n = 68)CDAI < 150
P
Urine m-ALB (>18 μg/min)
16.3
11.7
NS
13.3
4.4
0.06
Urine β2 mGLB (>120 μg/min)
40.8
16.6
< 0.001
53.3
22.1
< 0.05
Urine β-NAG (>5.9 U/L)
26.5
6.2
< 0.001
13.3
7.4
NS
Table 2 Microproteinuria and creatinine clearance in active and inactive IBD (mean±SE)
Ulcerative colitis (n = 194)
Crohn's disease (n = 83)
Active(n=49)
Inactive(n=145)
P
Active(n=15)
Inactive(n=68)
P
Urine m-ALB (μg/min)
11.89 ± 3.19
9.0 ± 1.03
NS
8.59 ± 2.65
7.02 ± 1.07
NS
Urine β2mGLB (μg/min)
204 ± 50.2
88.0 ± 10.28
<0.01
359 ± 130.9
92.2 ± 16.26
<0.05
Urine β-NAG (U/L)
4.69 ± 0.64
2.39 ± 0.16
<0.001
3.07 ± 0.90
2.36 ± 0.25
NS
Urine Kcr (mL/min)
114.4 ± 6.03
120.3 ± 3.24
NS
135.6 ± 8.34
127.7 ± 3.96
NS
Table 4 Correlation between microproteinuria in patients with ulcerative colitis and disease activity parameters (n=194 measurements)
Ulcerative colitis activity parameters
UCAI
UCEI
CRP
ESR
Platelets
SerumTNF-α
Urine m-ALB
rS
0.0283
0.0420
0.0232
0.0091
0.0826
0.1665
(μg/min)
P
0.6954
0.5612
0.7479
0.9001
0.2520
0.0203
Urine β2mGLB
rS
0.1957
0.1037
0.1059
0.0033
0.0540
0.0123
(μg/min)
P
0.0062
0.1501
0.1414
0.9634
0.4543
0.8648
Urine β-NAG
rS
0.2633
0.2335
0.1438
0.1224
0.2336
0.1057
(U/L)
P
0.0002
0.0010
0.0455
0.0891
0.0010
0.1426
Table 5 Correlation between microproteinuria in patients with Crohn’s disease and disease activity parameters (n=83 measurements)
Crohn's disease activity parameters
CDAI
CRP
ESR
Platelets
SerumTNF-α
Urine m-ALB
rS
0.1186
0.0326
0.0352
0.1483
0.1537
(μg/min)
P
0.2856
0.7686
0.7522
0.1810
0.1654
Urine β2mGLB
rS
0.0813
0.0187
0.0624
0.1727
0.2100
(μg/min)
P
0.4648
0.8669
0.5751
0.1184
0.0568
Urine β-NAG
rS
0.1106
0.0319
0.0947
0.0527
0.2676
(U/L)
P
0.3196
0.7744
0.3347
0.6359
0.0145
Table 3 Correlation of microproteinuria and creatinine clearance of IBD patients after 5-ASA treatment (mean±SE)
Ulcerative colitis (n=194)5-ASA treatment
P
Crohn's disease (n=83)5-ASA treatment
P
No (n=37)
Yes (n=157)
No (n=15)
Yes (n=68)
Urine m-ALB (μg/min)
8.99 ± 2.10
9.90 ± 1.29
0.794
8.08 ± 2.57
7.13 ± 1.08
0.562
Urine β2mGLB (μg/min)
163 ± 61.16
107 ± 12.07
0.852
274 ± 129.2
111.0 ± 20.15
0.083
Urine β-NAG (U/L)
4.22 ± 0.82
2.67 ± 0.18
0.118
2.79 ± 0.91
2.42 ± 0.26
0.845
Urine Kcr (mL/min)
117 ± 7.25
119 ± 3.11
0.987
130 ± 7.62
129 ± 4.05
0.713
Citation: Poulou AC, Goumas KE, Dandakis DC, Tyrmpas I, Panagiotaki M, Georgouli A, Soutos DC, Archimandritis A. Microproteinuria in patients with inflammatory bowel disease: Is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J Gastroenterol 2006; 12(5): 739-746